Literature DB >> 3103454

IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases.

J A Strauchen, B A Breakstone.   

Abstract

Interleukin-2 (IL-2) receptor expression is a feature of T-cell activation and T-cell neoplasia. Expression of the IL-2 receptor in human lymphoid lesions was studied in a series of 166 immunophenotyped cases, including nodal and extranodal reactive lymphoid proliferations (44 cases), low-grade B-cell lymphomas (27 cases), intermediate and high grade B cell lymphomas (42 cases), peripheral T-cell lymphomas (13 cases), Hodgkin's disease (12 cases), histiocytic proliferations (15 cases), nonhematopoietic tumors (16 cases), and miscellaneous lesions (7 cases). Low levels of receptor expression were seen in reactive lymphoid lesions, low-grade B-cell lymphomas, and nonhematopoietic tumors (20%, 7%, and 25% of cases, respectively, with greater than 10% positive cells). High levels of receptor expression were seen in cases of peripheral T-cell lymphoma and histiocytic proliferations (86% and 100% of cases, respectively, with greater than 10% positive cells). Intermediate levels of expression were seen in Hodgkin's disease (including Reed-Sternberg cells) and some cases of intermediate and high-grade B-cell lymphomas (58% and 50% of cases, respectively, with greater than 10% positive cells). IL-2 receptor expression is not confined to T-cell neoplasia, but is also a feature of neoplastic and nonneoplastic histiocytic proliferations, Hodgkin's disease, and some intermediate and high-grade B-cell lymphomas. Biologic and therapeutic implications are discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3103454      PMCID: PMC1899648     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  14 in total

1.  Selective in vitro growth of T lymphocytes from normal human bone marrows.

Authors:  D A Morgan; F W Ruscetti; R Gallo
Journal:  Science       Date:  1976-09-10       Impact factor: 47.728

2.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

3.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

Authors:  T Uchiyama; S Broder; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

4.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells.

Authors:  T Uchiyama; D L Nelson; T A Fleisher; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

5.  The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes.

Authors:  T A Waldmann
Journal:  Science       Date:  1986-05-09       Impact factor: 47.728

6.  Phenotypic expression of Hodgkin's and Reed-Sternberg cells in Hodgkin's disease.

Authors:  S M Hsu; K Yang; E S Jaffe
Journal:  Am J Pathol       Date:  1985-02       Impact factor: 4.307

7.  Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor.

Authors:  T A Waldmann; W C Greene; P S Sarin; C Saxinger; D W Blayney; W A Blattner; C K Goldman; K Bongiovanni; S Sharrow; J M Depper
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

8.  Hairy cell leukemia: a B cell neoplasm with a unique antigenic phenotype.

Authors:  S M Hsu; K Yang; E S Jaffe
Journal:  Am J Clin Pathol       Date:  1983-10       Impact factor: 2.493

9.  Stable expression of cDNA encoding the human interleukin 2 receptor in eukaryotic cells.

Authors:  W C Greene; R J Robb; P B Svetlik; C M Rusk; J M Depper; W J Leonard
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

10.  Detection and functional studies of p60-65 (Tac antigen) on activated human B cells.

Authors:  L K Jung; T Hara; S M Fu
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  16 in total

1.  Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis.

Authors:  G Delsol; T Al Saati; K C Gatter; J Gerdes; R Schwarting; P Caveriviere; F Rigal-Huguet; A Robert; H Stein; D Y Mason
Journal:  Am J Pathol       Date:  1988-01       Impact factor: 4.307

Review 2.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

3.  Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.

Authors:  Christian M Capitini; Terry J Fry; Crystal L Mackall
Journal:  Am J Immunol       Date:  2009-01-01

4.  90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.

Authors:  John E Janik; John C Morris; Deirdre O'Mahony; Stefania Pittaluga; Elaine S Jaffe; Christophe E Redon; William M Bonner; Martin W Brechbiel; Chang H Paik; Millie Whatley; Clara Chen; Jae-Ho Lee; Thomas A Fleisher; Maggie Brown; Jeffrey D White; Donn M Stewart; Suzanne Fioravanti; Cathryn C Lee; Carolyn K Goldman; Bonita R Bryant; Richard P Junghans; Jorge A Carrasquillo; Tat'Yana Worthy; Erin Corcoran; Kevin C Conlon; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-05       Impact factor: 11.205

Review 5.  A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine.

Authors:  Narendranath Epperla; Mehdi Hamadani
Journal:  Curr Hematol Malig Rep       Date:  2021-01-25       Impact factor: 3.952

6.  Failure of treatment with interleukin-2 receptor-specific monoclonal antibody in acute coxsackievirus B3 myocarditis in mice.

Authors:  C Kishimoto; Y Hiraoka; H Takada; M Kurokawa; H Ochiai
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

Review 7.  Immunoconjugates and long circulating systems: origins, current state of the art and future directions.

Authors:  Alexander Koshkaryev; Rupa Sawant; Madhura Deshpande; Vladimir Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2012-09-03       Impact factor: 15.470

8.  Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration.

Authors:  Daniel J Powell; Peter Attia; Victor Ghetie; John Schindler; Ellen S Vitetta; Steven A Rosenberg
Journal:  J Immunother       Date:  2008 Feb-Mar       Impact factor: 4.456

Review 9.  Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.

Authors:  Robert J Kreitman
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

10.  IL-2 mRNA expression in Tac-positive malignant lymphomas.

Authors:  M Peuchmaur; D Emilie; M C Crevon; P Solal-Celigny; M C Maillot; G Lemaigre; P Galanaud
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.